6.53
price down icon0.46%   -0.03
pre-market  Pre-market:  6.54   0.010   +0.15%
loading
Coya Therapeutics Inc stock is traded at $6.53, with a volume of 86,603. It is down -0.46% in the last 24 hours and down -1.80% over the past month. Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.
See More
Previous Close:
$6.56
Open:
$6.83
24h Volume:
86,603
Relative Volume:
0.92
Market Cap:
$87.97M
Revenue:
-
Net Income/Loss:
$-14.88M
P/E Ratio:
-6.6633
EPS:
-0.98
Net Cash Flow:
$-10.29M
1W Performance:
+24.14%
1M Performance:
-1.80%
6M Performance:
-34.11%
1Y Performance:
-22.35%
1-Day Range:
Value
$6.32
$6.9094
1-Week Range:
Value
$5.0595
$7.05
52-Week Range:
Value
$4.65
$10.24

Coya Therapeutics Inc Stock (COYA) Company Profile

Name
Name
Coya Therapeutics Inc
Name
Phone
650.739.3939
Name
Address
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
Name
Employee
8
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
COYA's Discussions on Twitter

Compare COYA with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
COYA
Coya Therapeutics Inc
6.53 87.97M 0 -14.88M -10.29M -0.98
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-24 Initiated D. Boral Capital Buy

Coya Therapeutics Inc Stock (COYA) Latest News

pulisher
03:33 AM

Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN

03:33 AM
pulisher
Apr 24, 2025

Coya Therapeutics Announce Positive Interim Result from - openPR.com

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia – EventsNewsAsia.com - eventsnewsasia.com

Apr 24, 2025
pulisher
Apr 24, 2025

Biotech Discovers Revolutionary Immunotherapy in Houston - streetwisereports.com

Apr 24, 2025
pulisher
Apr 24, 2025

Coya stock in focus after interim results for dementia drug - Seeking Alpha

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Reports Positive Data From Proof Of Concept Open-label Study Of IL-2 And CTLA4-Ig Combo In FTD - Nasdaq

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal Dementia - businessnews.ph

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics Announces Positive Interim Results Of An Investigator-Initiated Open Label Study With Low-Dose IL-2 And CTLA4-Ig Combination Treatment In Five Patients With Mild To Moderate Frontotemporal Dementia - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Revolutionary Frontotemporal Dementia Treatment Prevents Cognitive Decline in All Trial Patients - Stock Titan

Apr 24, 2025
pulisher
Apr 24, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from D. Boral Capital - Defense World

Apr 24, 2025
pulisher
Apr 23, 2025

Wall Street Analysts See a 144.73% Upside in Coya Therapeutics, Inc. (COYA): Can the Stock Really Move This High? - Yahoo Finance

Apr 23, 2025
pulisher
Apr 22, 2025

AI in Clinical Trials Market Growth 2025: Trends, Consumer - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Coya Therapeutics (NASDAQ:COYA) Trading 8.6% Higher – What’s Next? - Defense World

Apr 22, 2025
pulisher
Apr 21, 2025

Coya Therapeutics, Inc. Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death) - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

(COYA) Long Term Investment Analysis - news.stocktradersdaily.com

Apr 20, 2025
pulisher
Apr 11, 2025

Is Coya Therapeutics (COYA) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Yahoo Finance

Apr 11, 2025
pulisher
Apr 10, 2025

Coya Therapeutics stock hits 52-week low at $4.72 - Investing.com Australia

Apr 10, 2025
pulisher
Apr 09, 2025

Coya Therapeutics stock hits 52-week low at $4.72 By Investing.com - Investing.com Canada

Apr 09, 2025
pulisher
Apr 02, 2025

Exosomes Pipeline 2025: MOA and ROA Insights, Clinical Trials - openPR.com

Apr 02, 2025
pulisher
Apr 01, 2025

Coya Therapeutics Selected for Platform Presentation at the ADPD 2025 Conference in Vienna on April 5, 2025 - The Joplin Globe

Apr 01, 2025
pulisher
Mar 31, 2025

GMP Production of Exosomes Slated for Later This Year - streetwisereports.com

Mar 31, 2025
pulisher
Mar 29, 2025

D. Boral Capital Reiterates Buy Rating for Coya Therapeutics (NASDAQ:COYA) - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

Biotech Advances Revolutionary Treatment for Neurodegenerative Diseases - Streetwise Reports

Mar 28, 2025
pulisher
Mar 28, 2025

What is Chardan Capital’s Forecast for COYA FY2025 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

What Makes Coya Therapeutics, Inc. (COYA) a New Buy Stock - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Wall Street Analysts Think Coya Therapeutics, Inc. (COYA) Could Surge 149.62%: Read This Before Placing a Bet - Yahoo Finance

Mar 27, 2025
pulisher
Mar 27, 2025

Are Medical Stocks Lagging Auna S.A. (AUNA) This Year? - Yahoo

Mar 27, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics advances Treg exosome production - Investing.com India

Mar 26, 2025
pulisher
Mar 26, 2025

Coya Therapeutics Reports Progress from an Academic Supported First-in-Class Treg-derived Exosome Program - Joplin Globe

Mar 26, 2025
pulisher
Mar 26, 2025

Revolutionary Treg Exosome Treatment Could Transform Neurodegenerative Disease Therapy - Stock Titan

Mar 26, 2025
pulisher
Mar 25, 2025

Agitation in Alzheimer's Disease Market: Analysis - openPR.com

Mar 25, 2025
pulisher
Mar 24, 2025

(COYA) Trading Report - news.stocktradersdaily.com

Mar 24, 2025
pulisher
Mar 22, 2025

Coya Therapeutics (NASDAQ:COYA) Earns Buy Rating from Chardan Capital - Defense World

Mar 22, 2025
pulisher
Mar 21, 2025

Coya Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 21, 2025
pulisher
Mar 20, 2025

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference. - Business Wire

Mar 20, 2025
pulisher
Mar 20, 2025

Coya Therapeutics (NASDAQ:COYA) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance

Mar 20, 2025
pulisher
Mar 20, 2025

BTIG maintains Buy on Coya Therapeutics, target at $15 By Investing.com - Investing.com Canada

Mar 20, 2025
pulisher
Mar 19, 2025

Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World

Mar 19, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Reports 2024 Financial Results and Updates - TipRanks

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics, Inc. SEC 10-K Report - TradingView

Mar 18, 2025
pulisher
Mar 18, 2025

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2024 Financial Results - Business Wire

Mar 18, 2025
pulisher
Mar 15, 2025

Coya Therapeutics, Inc. Announces Closing of $15.25 Million Initial Public Offering - Business Wire

Mar 15, 2025
pulisher
Mar 15, 2025

Coya Therapeutics Announces Closing of $26.5 Million Private Placement - Business Wire

Mar 15, 2025
pulisher
Mar 14, 2025

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Mar 14, 2025
pulisher
Mar 13, 2025

Where are the Opportunities in (COYA) - Stock Traders Daily

Mar 13, 2025
pulisher
Mar 11, 2025

Coya Therapeutics (COYA) to Release Earnings on Tuesday - Defense World

Mar 11, 2025
pulisher
Mar 11, 2025

D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - The AM Reporter

Mar 11, 2025
pulisher
Mar 11, 2025

Coya Therapeutics’ (COYA) “Buy” Rating Reaffirmed at D. Boral Capital - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Market Watch Highlights: Coya Therapeutics Inc (COYA) Ends on an Upturn Note at 6.88 - The Dwinnex

Mar 10, 2025
pulisher
Mar 08, 2025

EXCLUSIVE: Coya Therapeutics, Focused On Neurodegenerative Diseases Has Gained 70% Since IPO; CEO Highlights Efforts On Combination Therapy For Rare Diseases - MSN

Mar 08, 2025

Coya Therapeutics Inc Stock (COYA) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Coya Therapeutics Inc Stock (COYA) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Swaminathan Arun
Chief Executive Officer
Nov 13 '24
Buy
7.36
5,000
36,797
10,000
Grossman Fred
Chief Medical Officer
Nov 11 '24
Buy
7.37
2,710
19,973
2,710
Swaminathan Arun
Chief Executive Officer
Nov 11 '24
Buy
7.34
5,000
36,689
5,000
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):